| Randomized controlled trial |
| Jiang et al. 21) (2023) | Post-traumatic | Guizhi-tang (桂枝湯), TID | NA | OT | OT | 6M |
| Drews et al. 10) (2022) | Post-viral | NA | 2 times/week12 sessions in totalDuration 30minAcupoint (LI20, LI4, SP6, ST44, Bl 3, LG23, NP 12, Op 16,) | NA | Sham acupuncture2times/week,12 sessions in totalDuration 30minAcupoint (fake acupuncture point at Deltoideous, Upper Arm, Thigh, Back) | 6W |
| Retrospective cohort study |
| Vent, et al 22) (2010) | Post-viral | NA | 1time/week,10 sessions in totalDuration 30minAcupoint (GV16, GV20, LI20, LU7, LU9, ST36, KI3) | NA | oral vitamin B complexover 12 weeks | TG :10WCG:12W |
| Ono et al. 4) (2022) | Post-viral (COVID-19) | Used multiple formulas in combination a | NA | Partially combined with WM b | Some untreated(n=11),some received WM(n=24) | NR |
| Retrospective observational study |
| Park, et al 12) (2019) | post-viral, sinonasal, traumatic, unknown | Tongqiao Tang (通竅湯)Jiantong Daotan Tang (肩痛導痰湯)Xuanfang Baidu Tang (宣方敗毒湯)Buxin Jianpi Tang (補心健脾湯)TID | 1-2times/week,Duration 15minAcupoint (GV20, GV23, EX-HN3, LI20, GB20, CV21, BL1, LU7, LI4, LI11, SI3, ST36, SP6, LR3) | - Electro-moxibustion applied to bilateralLI20 and GV20 for 10 minutes,1–2 times/week- Intranasal administration of anti-inflammatory herbal extract (0.25 cc per nostril),1–2 times/week- OT for 12 weeks | NA | 12W |
| Case report |
| Im, et al 16) (2024) | Unspecified | Mahuang-jia-Zhushu Tang (麻黃加朮湯)BID | 5 sessions in totalDuration 20minAcupoint (LI20, EX-HN8, LI4, ST36, SI3) | NA | NA | 35D |
| Bhat et al. 11) (2023) | Post-viral (COVID-19) | NA | 7 sessions in totalDuration 20minAcupoint (GV20, LI20, Ex-HN3, HT7, LI11, GB8, GB21, GV25) | Ayurvedic therapy: Shadbindu taila marsha nasya for 7 days, followed by pratimarsha nasya for 4 months + oral intake of Naradiya Laxmivilasa Rasa (TID for 1 month)" | NA | |
| Morita et al. 13) (2022) | Post-viral (COVID-19) | C1: Jiawei Guipi Tang (加味歸脾湯)C2: Renshen Yangrong Tang (人蔘養榮湯) | 1-2times/week,Duration 15minAcupoint (LI20, HT7, SP9, BL10, BL14, BL15, KI3, PC6, PC7, GB20, LR3, CV7, GV12, GV20) | NA | NA | 7-8 M |
| Takayama et al. 5)(2021) | Post-viral (COVID-19) | Gegen-tangjia Chuanxiong Xinyi (葛根湯加川芎辛夷)7.5 g/day (divided into 3 doses) | NA | NA | NA | 3-5 D |
| Hunter, et al 17) (2021) | Post-viral | NA | 6 sessions2–4 week intervalsDuration 10minAcupoint (BL2, LI20, CV24, GV20, GV22, GV24, GV26, EX-HN3) | NA | NA | 3M |
| Kang, et al 18) (2018) | Sinonasal (chronic rhinosinusitis) | C1:- Tongqiao Tang (通竅湯) BID~TID- Jingfang Xiebai San(荊防瀉白散) BID,- Qingyin Lige Tang(淸因理膈湯)QDC2- Used multiple formulas in combination cTID or BID depending on prescription | 2 times/week,15 Sessions in totalDuration 15 minAcupoint (EX-B2 (C3-7), GV14, GV13, BL11, LI20, EX-HN8, EX-HN9, ST7) | NA | NA | C1:2MC2: 10W |
| Jeon et al.19) (2017) | Post-viral, Sinonasal | C1 :- Jingjie Lianqiao Tang (荊芥連翹湯), - Bofu-tsusho-san (防風通聖散) (4g, BID)C2 : Jiawei Erchen Tang (加味二陳湯) (120cc, BID) | 1-2times/weekDuration 15 minAcupoint (EX-HN3, LI20, Intranasal acupuncture) | Nasal lasers irradiated for 5minutes1-2times/week | NA | C1: 55DC2: 23D |
| Moon et al.20)(2017) | Post-viral, | Danggui Shaoyao San (當歸芍藥散) TID | 1time/week15 sessions in totalDuration 15 minAcupoint (Ex-HN3, GV20, GV23, LI4, LR3, LI20, EX-HN8) | NA | NA | 95D |